Previous 10 | Next 10 |
bluebird bio (NASDAQ: BLUE ): Q1 GAAP EPS of -$2.99 misses by $0.16 . Revenue of $12.5M (-21.7% Y/Y) misses by $2.99M . Press Release More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news,
– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have β 0 /β 0 genotype ...
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’ lead investigational BCMA-targeted chimeric antige...
bluebird bio, Inc. (Nasdaq: BLUE), has appointed Joanne Smith-Farrell, Ph.D., to chief business officer. In this role, Joanne will lead corporate development and strategy, and she will also continue to serve as our oncology franchise leader. “Under Joanne’s leadership, blue...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
Novartis's 8.7 billion bet Last year Novartis ( NVS ) made waves by acquiring the gene therapy company AveXis for an astounding 8.7 billion dollars , setting in motion a rush of additional buyouts in this therapeutic space including Spark Therapeutics (4.8 billion) and Nightstar Therapeu...
bluebird bio ( BLUE ) is one step closer to potentially obtaining European approval for its gene therapy Zynteglo. That's because the Committee for Medicinal Products for Human Use ((CHMP)) recommended that the gene therapy product should be approved for the European Union. If bluebird get...
NetworkNewsWire Editorial Coverage : Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs u...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...